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www.jacctctabstracts2014.com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PMResults: Pre-procedural EF was not different between two groups (34.3  5.9 vs. 32.4
 6.2%, P¼0.10). The CABG group included more patients with triple-vesseldisease
(P< 0.001) and the PCI group included more patients with presenting with myocardial
infarction (MI) (P¼0.002). At 2 years, death occurred in 7 (17.1%) of the PCI group
and 27 (15.7%) of the CABG group (P¼0.73). The composite of death, MI or stroke
occurred in 8 (19.5%) of the PCI group and 30 (17.4%) of the CABG group (P¼0.63).
The rates of target-vessel revascularization were signiﬁcantly higher in the PCI group
(4.9% vs. 0%, P¼0.003). After adjustment for the baseline characteristics, hazard ratio
was 0.94 (95% CI, 0.39w2.23; P¼0.88) for death; 0.99 (95% CI, 0.44w2.23;
P¼0.98) for the death, MI, or stroke; 186.6 (95% CI, contain 0; P¼0.58) for target-
vessel revascularization.
Conclusions: In patients with ULMCA disease and severe LVD, PCI and CABG
showed similar clinical outcomes at 2 year follow-up.
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Background: Percutaneous coronary intervention (PCI) for unprotected left main
trunk (ULMT), especially with single stent strategy, has favorable outcome with
advent of drug eluting stent (DES). Direct comparison of the outcome between PCI
with single stent strategy for ULMT bifurcation lesion and left anterior descending
artery (LAD) is lacking. The aim of this study is to testify the long-term feasibility of
PCI for ULMT bifurcation lesion with single stent strategy by comparison with LAD
lesion.
Methods:We investigated retrospectively 105 consecutive patients (mean age: 69.3
years old, female: 21.0% and diabetes mellitus: 38.1%) who were treated by siro-
limus eluting stent (SES) implantation with single stent strategy for ULMT bifur-
cation disease from August 2004 to December 2010 in our center. We compared
them with a matched group of 105 patients who underwent SES implantation for
LAD lesion with the same strategy. Matching criteria was identical age, gender and
presence of diabetes mellitus. All the cases were done with intravascular ultrasound
guidance. We assessed occurrence of MACE (a composite of cardiac death, non-
fatal acute myocardial infarction (AMI) and target lesion revascularization (TLR)),
cardiac death, AMI, stent thrombosis and TLR. Mean follow-up period was
65.328.4 months.
Results: There were no statistical differences in MACE and other endpoints between
the two groups (Figure). A favorable trend for ULMT lesion was shown in MACE
(p¼0.09).Conclusions: DES implantation with single stent strategy for ULMT bifurcation
lesion provides as feasible long-term outcome as for LAD lesion.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/CoTCT-229
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Background: Clinical outcomes after treatment of ostial/midshaft lesions in unpro-
tected left main coronary artery (ULMCA) with ﬁrst generation drug-eluting stents
(DES) have been found to be favorable. However, to date, data regarding new gen-
eration DES for these lesion subsets have not been reported. The aim of this study was
to compare the clinical outcomes following ULMCA percutaneous coronary inter-
vention (PCI) of ostial/midshaft lesions with ﬁrst versus new generation DES.
Methods: A total of 219 patients from the Milan New-Tokyo (MITO) registry with
ostial/midshaft lesions in ULMCA treated with ﬁrst (n¼139) or new generation DES
(n¼80) were analyzed.
Results: The ﬁrst generation DES group had more males (78.4% vs. 63.8%,
p¼0.026). There was a higher prevalence of IVUS use (35.2% vs. 50.0%, p¼0.032)
and post-dilation (70.5% vs. 93.8%, p < 0.001) with larger maximum balloon
diameter (3.810.45 vs. 4.080.44, p < 0.001) in the new generation DES group. At
a median follow-up period of 730 days, there were no signiﬁcant differences in the
propensity-score adjusted analyses, for major adverse cardiac events (MACE) deﬁned
as composite endpoint of all-cause death, myocardial infarction and target vessel
revascularization (HR [new vs. ﬁrst generation DES]: 1.22; 95% CI: 0.64 to 2.31;
p¼0.549). Of note, target lesion revascularization rates at 2-years were only 0.9% and
2.7%, for ﬁrst and new generation DES groups, respectively (p¼0.339). On multi-
variable analysis, SYNTAX score (HR: 1.06; 95% CI: 1.02-1.11, p¼0.006) and
EuroSCORE (HR: 1.14; 95% CI: 1.00-1.31, p¼0.051) were independent predictors
for MACE.
Conclusions: This study suggests that new generation DES for ostial/midshaft lesions
in ULMCA are associated with favorable clinical outcomes, comparable to those
observed with ﬁrst generation DES.
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Background: Percutaneous coronary intervention (PCI) with drug eluting stent
(DES) implantation for left main coronary artery (LMCA) stenosis has been shown
to be a feasible and safe approach. However, optimal stenting technique is still
under discussion. Our goal is to evaluate safety and efﬁcacy of novel stenting
technique in LM distal lesions - intravascular ultrasound (IVUS) guided and op-
tical coherence tomography (OCT) optimized everolimus eluting platinum chro-
mium stent (SYNERGY) and bioresorbable coronary scaffold (ABSORB)
implantation.
Methods: 31 patient with distal LMCA are enrolled in ongoing study at Latvian
Center of Cardiology. All interventions were IVUS guided and OCT optimized.
Plaque modiﬁcation with cutting balloon before stenting was performed. SYNERGY
stent was implanted across the CX followed by ABSORB implantation at the proximal
CX. Procedure is ﬁnished with “kissing” post-dilation. 12-month angiographic, IVUS
and OCT follow-up is ongoing.
Results: All patients underwent the procedure due to stable angina, 25 (81%) of them
were males. Mean patient age was 6211 years, 26 (85%) of them were hypertonic
with dyslipidemia, 7 (23%) suffered from diabetes mellitus and were smokers. Mean
SYNTAX score 27,62,6. Synergy stent length implanted in LM-LAD was 236,53
mm, diameter 3,750,27mm. Mean Absorb scaffold length implanted in LM-LCX
was 163,10 mm, diameter 3,20,52 mm. Stenting technique: modiﬁed T stenting 10
cases, mini – Crush 21.There were no procedural complications. No major cardiac
adverse events occurred during hospitalization period and 30 day follow-up.
Conclusions: The current study demonstrates that novel LMCA stenting technique
using SYNERGY stent and ABSORB scaffold is safe and feasible. No seriousronary Lesions - Left Main B67
